What does ADMIT mean in DISEASES
ADMIT is an acronym short for Arterial Disease Multiple Intervention Trial. It is a research study of multi-center trials that investigate the effects of multiple interventions to reduce cardiovascular disease in individuals with high risk factors. This research was funded by the National Institutes of Health, and coordinated by Brigham and Women’s Hospital in Boston, Massachusetts. The main objective of this study was to determine the efficacy, safety, and long-term benefits of interventions such as lifestyle modifications (including diet and physical activity), drug therapies, and other treatments in reducing occurrence of heart attack or stroke in persons at high risk for these events.
ADMIT meaning in Diseases in Medical
ADMIT mostly used in an acronym Diseases in Category Medical that means Arterial Disease Multiple Intervention Trial
Shorthand: ADMIT,
Full Form: Arterial Disease Multiple Intervention Trial
For more information of "Arterial Disease Multiple Intervention Trial", see the section below.
ADMIT Meaning in Medical
The Arterial Disease Multiple Intervention Trial (ADMIT) was a randomized clinical trial designed to evaluate the effectiveness of combining lifestyle modification with treatment with cholesterol-lowering drugs compared with treatment alone on preventing cardiovascular disease in individuals with pre-existing arterial disease. The study enrolled over 6500 patients from 76 centers across the United States between October 2001 and January 2005. Study participants were randomly assigned to either receive usual care or an intervention arm consisting of therapeutic lifestyle changes along with pharmacologic therapy (statin). The primary outcome used to assess the efficacy of the intervention was a composite endpoint including nonfatal myocardial infarction, nonfatal stroke, coronary revascularization or death due to any cause.
Essential Questions and Answers on Arterial Disease Multiple Intervention Trial in "MEDICAL»DISEASES"
What is ADMIT?
ADMIT stands for the Arterial Disease Multiple Intervention Trial. It is an international, collaborative effort that seeks to improve the management of arterial disease through implementation of preventive strategies and better treatment.
What is the scope of the ADMIT trial?
The ADMIT trial involves a prospective study of more than 20,000 participants in over 30 countries worldwide. The goal is to evaluate strategies for prevention and better management of arterial disease including cerebrovascular disease, peripheral artery disease, and coronary artery disease.
Why was the ADMIT trial created?
The ADMIT Trial was created in response to increasing rates and trends in arterial diseases worldwide. By providing a comprehensive assessment of various strategies for prevention and management, it is hoped that this will lead to improved patient outcomes.
Who is eligible to participate in the ADMIT trial?
Eligibility criteria may vary by country, but generally include adults between 40-80 years old with at least one major risk factor for cardiovascular events such as high blood pressure or cholesterol levels. Patients must not have any history or existing diagnosis of cardiovascular disease.
How long does it take to complete the trial?
The typical duration of participation in the ADMIT trial is three years, however it can be less if there are no complications or further interventions required during that period.
What type of interventions are used in the ADMIT trial?
Interventions used in the trial may include lifestyle modifications such as diet and exercise regimens; medications such as aspirin or statins; surgical treatments; or other preventive strategies such as smoking cessation programs.
Is there a cost associated with participating in the ADMIT trial?
Most costs associated with participation in the trial are covered by insurance companies or other third parties and therefore do not incur out-of-pocket expenses for participants. However, there may be some additional fees required for lab testing or diagnostic imaging procedures outside of regular care visits which could be subject to co-payment depending on your plan coverage.
Are there risks associated with participation in the ADMIX Trial?
As with any medical intervention, there are potential risks associated with participation in clinical trials such as side effects from drugs being administered or possible adverse reactions from other interventions attempted during treatment periods. However these risks are mitigated through informed consent processes throughout each stage and periodically reviewed throughout participation.
Are results from prior studies available regarding efficacy/safety outcomes from previous trials conducted under similar protocols?
Yes, there has been numerous research studies conducted under similar protocols relating to arterial diseases which have produced positive results that were published across multiple peer-reviewed journals demonstrating safety/efficacy outcomes.
Final Words:
In conclusion, Arterial Disease Multiple Intervention Trial (ADMIT) is a research study conducted by Brigham and Women’s Hospital which aimed at determining whether combining therapeutic lifestyle intervention along with drug therapies could reduce incidence rate cardiovascular diseases such as heart attack or stroke among high risk individuals. ADMIT showed positive results indicating that intensive use of combination therapy can lead to improved outcomes for patients suffering from arterial disease as compared to conventional care only.